Cargando…
Treatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report
RATIONALE: Castleman's disease (CD) is a rare lymphoproliferative disease. Compared to unicentric CD, multicentric Castleman disease (MCD) displays poorer prognosis and great variance to different therapies. Though chemotherapy, immunization therapy, and glucocorticoids have been used in the tr...
Autores principales: | Cai, Sisi, Zhong, Zhaodong, Li, Xiang, Wang, Hong Xiang, Wang, Li, Zhang, Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6867793/ https://www.ncbi.nlm.nih.gov/pubmed/31725610 http://dx.doi.org/10.1097/MD.0000000000017681 |
Ejemplares similares
-
Role of autoimmune hemolytic anemia as an initial indicator for chronic myeloid leukemia: A case report
por: Li, Xiang, et al.
Publicado: (2020) -
Randomized, double-blind, placebo-controlled, parallel-group trial of sirolimus for tocilizumab-resistant idiopathic multicentric Castleman disease: Study protocol for clinical trial
por: Koga, Tomohiro, et al.
Publicado: (2020) -
An open-label continuation trial of sirolimus for tocilizumab-refractory idiopathic multicentric Castleman disease: Study protocol for an investigator-initiated, multicenter, open-label trial (SPIRIT compliant)
por: Koga, Tomohiro, et al.
Publicado: (2020) -
Peripheral T cell lymphoma coexisting with Castleman's disease: A case report and literature review
por: Liu, Shuyan, et al.
Publicado: (2020) -
Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report
por: Hu, Shaoxuan, et al.
Publicado: (2020)